Last Price
1.90
Today's Change
+0.22 (13.09%)
Day's Change
1.67 - 1.96
Trading Volume
3,540,508
Market Cap
610 Million
Shares Outstanding
321 Million
Avg Volume
2,206,807
Avg Price (50 Days)
2.69
Avg Price (200 Days)
5.21
PE Ratio
-11.87
EPS
-0.16
Earnings Announcement
20-Aug-2025
Previous Close
1.68
Open
1.59
Day's Range
1.675 - 1.96
Year Range
1.43 - 8.975
Trading Volume
3,540,508
1 Day Change
13.10%
5 Day Change
18.75%
1 Month Change
-32.38%
3 Month Change
-51.78%
6 Month Change
-71.98%
Ytd Change
-53.20%
1 Year Change
-29.89%
3 Year Change
252.94%
5 Year Change
26.67%
10 Year Change
26.67%
Max Change
26.67%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.